Document is current
Any future updates will be listed below
-
Authors
Kirsch, Paul
Helbig, Miriam
Rupar, Dominic
Baudrexel, Simon
Kell, Christian A.
-
Funding
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Received: 24 December 2025
Accepted: 24 July 2026
First Online: 1 August 2026
Declarations
Ethics approval and consent to participate: The study was approved by the local ethics committee of the Medical Faculty of Goethe University (GZ 20–18). All participants gave written informed consent according to the Helsinki declaration.
Consent for publication: Not applicable.
Competing interests: CAK holds 5% of the shares of Novapace. SB supervised the analysis of the second cohort without any involvement of CAK to exclude any potential conflict of interest. The results of the first cohort were replicated in the second cohort.
